AUTL vs DBVT vs CABA vs SANA vs FATE

For growth investors, Autolus Therapeutics plc (AUTL) is the stronger pick with 496.

0% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Analysts rate Autolus Therapeutics plc (AUTL) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cabaletta Bio, Inc.

(CABA) delivered a total return of -58. 2%, compared to -96. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: FATE returned +40. 5% versus AUTL's -93. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DBV Technologies S.

A. (DBVT) is the lower-risk stock at 1. 26β versus Sana Biotechnology, Inc. 's 2. 69β — meaning SANA is approximately 114% more volatile than DBVT relative to the S&P 500. On balance sheet safety, Autolus Therapeutics plc (AUTL) carries a lower debt/equity ratio of 12% versus 38% for Sana Biotechnology, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Autolus Therapeutics plc (AUTL) is pulling ahead at 496.

0% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Cabaletta Bio, Inc. grew EPS 29. 9% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, AUTL leads at 88. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DBV Technologies S.

A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -21. 8% for Autolus Therapeutics plc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -23. 9% for AUTL. At the gross margin level — before operating expenses — DBVT leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, DBV Technologies S.

A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Sana Biotechnology, Inc. (SANA) carries a higher beta of 2. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -87. 0%, SANA: -90. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AUTL is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; CABA is a small-cap quality compounder stock; SANA is a small-cap quality compounder stock; FATE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.